$9.51
13.61% today
Nasdaq, Aug 12, 09:12 pm CET
ISIN
US31572Q8087
Symbol
FGEN

FibroGen, Inc. Stock price

$8.37
+1.22 17.06% 1M
-3.52 29.60% 6M
-4.87 36.77% YTD
-1.26 13.04% 1Y
-342.88 97.62% 3Y
-1,117.38 99.26% 5Y
-541.13 98.48% 10Y
-541.63 98.48% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.34 3.90%
ISIN
US31572Q8087
Symbol
FGEN
Industry

Key metrics

Basic
Market capitalization
$33.8m
Enterprise Value
$91.4m
Net debt
$57.6m
Cash
$33.6m
Shares outstanding
4.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.3 | 3.3
EV/Sales
0.9 | 9.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-105.2%
Return on Equity
21.1%
ROCE
-124.9%
ROIC
-122.3%
Debt/Equity
-0.4
Financials (TTM | estimate)
Revenue
$102.9m | $10.2m
EBITDA
$-112.5m | $-78.2m
EBIT
$-114.7m | $-72.3m
Net Income
$-10.0m | $-50.0m
Free Cash Flow
$-76.3m
Growth (TTM | estimate)
Revenue
-38.6% | -65.6%
EBITDA
50.9% | 39.0%
EBIT
51.6% | 44.8%
Net Income
95.8% | -5.0%
Free Cash Flow
72.2%
Margin (TTM | estimate)
Gross
109.7%
EBITDA
-109.4% | -768.1%
EBIT
-111.5%
Net
-9.7% | -490.6%
Free Cash Flow
-74.1%
More
EPS
$-2.5
FCF per Share
$-18.9
Short interest
3.8%
Employees
225
Rev per Employee
$130.0k
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

Buy
75%
Hold
25%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
103 103
39% 39%
100%
- Direct Costs -9.94 -9.94
124% 124%
-10%
113 113
11% 11%
110%
- Selling and Administrative Expenses 35 35
67% 67%
34%
- Research and Development Expense 66 66
73% 73%
65%
-112 -112
51% 51%
-109%
- Depreciation and Amortization 2.20 2.20
72% 72%
2%
EBIT (Operating Income) EBIT -115 -115
52% 52%
-112%
Net Profit -10 -10
96% 96%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
Seeking Alpha
about 16 hours ago
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Carol Gaddum - Corporate Participant Product Team Lead - Corporate Participant David DeLucia - Chief Financial Officer Thane Wettig - CEO & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Neutral
GlobeNewsWire
about 24 hours ago
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments.
Neutral
GlobeNewsWire
8 days ago
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 225
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today